Lam Thanh Phan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lam Thanh Phan has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Hang Thi Thu Nguyen
Department of Oncology and Radiotherapy, Viet Duc University Hospital, Hanoi, Vietnam
3 shared publications - Thau Manh Cao
Department of Oncology and Radiotherapy, Viet Duc University Hospital, Hanoi, Vietnam
3 shared publications - Trung Nghia Bui
Department of Oncology and Radiotherapy, Viet Duc University Hospital, Hanoi, Vietnam
3 shared publications Anh Gia Pham
Department of Oncology and Radiotherapy, Viet Duc University Hospital, Hanoi, Vietnam
2 shared publicationsCong Tien Bui
2 shared publicationsHang Thu Nong
2 shared publications
Latest Publications
- Open Access
- 1 August 2026
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 13, 1-12
Outcomes of Preoperative TACE vs Upfront Hepatectomy in Hepatocellular Carcinoma: A Single-Center Retrospective Study in Vietnam
Purpose: This propensity score-matched study aimed to compare survival outcomes between preoperative TACE followed by hepatectomy and upfront hepatectomy in patients with resectable hepatocellular carcinoma. Patients and Methods: In this single-center retrospective cohort study at Viet Duc University Hospital, 304 consecutive patients with resectable HCC treated between January 2015 and October 2024 were analyzed: 168 underwent upfront hepatectomy and 136 received preoperative TACE followed by hepatectomy. Propensity score matching (PSM; 1:1 nearest-neighbor, caliper 0.01) was performed to balance pre-treatment covariates between groups. Overall survival (OS) and disease-free survival (DFS) were compared using Kaplan–Meier analysis and the Log rank test. Independent prognostic factors were identified using multivariable Cox regression. Results: Median follow-up was 58.9 months. After PSM (113 matched pairs), median OS was not reached in the upfront hepatectomy group versus 62.5 months in the preoperative TACE group (P = 0.322), and median DFS was 32.0 versus 29.2 months (P = 0.056). In multivariable Cox analysis of the matched cohort, preoperative TACE was not independently associated with OS (HR 1.15, 95% CI 0.74– 1.79; P = 0.526) or DFS (HR 1.19, 95% CI 0.92– 1.75; P = 0.130), whereas advanced TNM stage (OS: HR 2.45, 95% CI 1.08– 5.52, P = 0.032; DFS: HR 2.26, 95% CI 1.14– 4.46, P = 0.019) and microvascular invasion (OS: HR 1.48, 95% CI 1.09– 2.40, P = 0.007; DFS: HR 1.52, 95% CI 1.01– 2.29, P = 0.035) remained independent prognostic factors. Within the TACE group, patients achieving complete pathological necrosis (n = 26) had OS and DFS comparable to upfront hepatectomy, whereas incomplete or partial necrosis was associated with significantly worse survival (P = 0.05 for OS and P = 0.01 for DFS). Conclusion: In this retrospective, propensity score-matched cohort, preoperative TACE was not associated with improved overall or disease-free survival in patients with resectable HCC and does not appear justified as a routine strategy in patients who are already surgical candidates. Because the analysis was retrospective and residual confounding cannot be excluded, these findings should be regarded as hypothesis-generating. Any role for preoperative TACE in selected settings, such as borderline resectability or when complete tumor necrosis is achieved, requires prospective confirmation.
- 1 August 2026
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 13, 1-12
Open AccessOutcomes of Preoperative TACE vs Upfront Hepatectomy in Hepatocellular Carcinoma: A Single-Center Retrospective Study in Vietnam
Purpose: This propensity score-matched study aimed to compare survival outcomes between preoperative TACE followed by hepatectomy and upfront hepatectomy in patients with resectable hepatocellular carcinoma. Patients and Methods: In this single-center retrospective cohort study at Viet Duc University Hospital, 304 consecutive patients with resectable HCC treated between January 2015 and October 2024 were analyzed: 168 underwent upfront hepatectomy and 136 received preoperative TACE followed by hepatectomy. Propensity score matching (PSM; 1:1 nearest-neighbor, caliper 0.01) was performed to balance pre-treatment covariates between groups. Overall survival (OS) and disease-free survival (DFS) were compared using Kaplan–Meier analysis and the Log rank test. Independent prognostic factors were identified using multivariable Cox regression. Results: Median follow-up was 58.9 months. After PSM (113 matched pairs), median OS was not reached in the upfront hepatectomy group versus 62.5 months in the preoperative TACE group (P = 0.322), and median DFS was 32.0 versus 29.2 months (P = 0.056). In multivariable Cox analysis of the matched cohort, preoperative TACE was not independently associated with OS (HR 1.15, 95% CI 0.74– 1.79; P = 0.526) or DFS (HR 1.19, 95% CI 0.92– 1.75; P = 0.130), whereas advanced TNM stage (OS: HR 2.45, 95% CI 1.08– 5.52, P = 0.032; DFS: HR 2.26, 95% CI 1.14– 4.46, P = 0.019) and microvascular invasion (OS: HR 1.48, 95% CI 1.09– 2.40, P = 0.007; DFS: HR 1.52, 95% CI 1.01– 2.29, P = 0.035) remained independent prognostic factors. Within the TACE group, patients achieving complete pathological necrosis (n = 26) had OS and DFS comparable to upfront hepatectomy, whereas incomplete or partial necrosis was associated with significantly worse survival (P = 0.05 for OS and P = 0.01 for DFS). Conclusion: In this retrospective, propensity score-matched cohort, preoperative TACE was not associated with improved overall or disease-free survival in patients with resectable HCC and does not appear justified as a routine strategy in patients who are already surgical candidates. Because the analysis was retrospective and residual confounding cannot be excluded, these findings should be regarded as hypothesis-generating. Any role for preoperative TACE in selected settings, such as borderline resectability or when complete tumor necrosis is achieved, requires prospective confirmation.
- Open Access
- 1 August 2026
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 18, 1-14
Prognostic Determinants of Disease-Free Survival After Curative Resection for Hepatocellular Carcinoma: A Retrospective Cohort Study
- 1 August 2026
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 18, 1-14
Open AccessPrognostic Determinants of Disease-Free Survival After Curative Resection for Hepatocellular Carcinoma: A Retrospective Cohort Study
- Open Access
- 7 May 2026
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26
Integrated clinicopathological model versus TNM for predicting survival in resected hepatocellular carcinoma: a retrospective cohort study
Objective: To explore prognostic factors of postoperative hepatocellular carcinoma (HCC) and compare the prognostic performance of the tumor–node–metastasis (TNM) system with an integrated clinicopathological model. Methods: We conducted a cohort study evaluating 249 patients with HCC who underwent radical liver resection between January 2015 and December 2024. Overall survival (OS) was the primary endpoint. Independent prognostic factors were determined using the Cox proportional hazards model. Model performance was assessed using the correlation index (C-index) with bootstrap internal validation. Time-dependent receiver operating characteristic (ROC) curves, decision curve analysis (DCA), and calibration plots were used to assess discrimination, clinical utility, and agreement between predicted and observed outcomes. Results: In multivariable analysis, TNM stage, microvascular invasion (MVI), resection margin status, and albumin–bilirubin (ALBI) grade were independent predictors of OS. For recurrence-free survival (RFS), independent predictors included hepatitis status, ALBI grade, TNM stage, and MVI. The integrated model demonstrated improved discrimination compared with TNM alone, with a higher optimism-corrected C-index (0.676 vs. 0.647). Time-dependent ROC analysis showed significantly higher AUC values for the integrated model at 1 year (0.725 vs. 0.669, p = 0.046), 3 years (0.703 vs. 0.657, p = 0.024), and 5 years (0.684 vs. 0.649, p = 0.031). DCA indicated greater net benefit across clinically relevant thresholds, and calibration plots showed good agreement between predicted and observed survival probabilities. Conclusion: An integrated clinicopathological model incorporating TNM stage, MVI, ALBI grade, and resection margin status improves prognostic performance compared with TNM alone in patients undergoing curative resection for HCC. This model may support more accurate postoperative risk stratification.
- 7 May 2026
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26
Open AccessIntegrated clinicopathological model versus TNM for predicting survival in resected hepatocellular carcinoma: a retrospective cohort study
Objective: To explore prognostic factors of postoperative hepatocellular carcinoma (HCC) and compare the prognostic performance of the tumor–node–metastasis (TNM) system with an integrated clinicopathological model. Methods: We conducted a cohort study evaluating 249 patients with HCC who underwent radical liver resection between January 2015 and December 2024. Overall survival (OS) was the primary endpoint. Independent prognostic factors were determined using the Cox proportional hazards model. Model performance was assessed using the correlation index (C-index) with bootstrap internal validation. Time-dependent receiver operating characteristic (ROC) curves, decision curve analysis (DCA), and calibration plots were used to assess discrimination, clinical utility, and agreement between predicted and observed outcomes. Results: In multivariable analysis, TNM stage, microvascular invasion (MVI), resection margin status, and albumin–bilirubin (ALBI) grade were independent predictors of OS. For recurrence-free survival (RFS), independent predictors included hepatitis status, ALBI grade, TNM stage, and MVI. The integrated model demonstrated improved discrimination compared with TNM alone, with a higher optimism-corrected C-index (0.676 vs. 0.647). Time-dependent ROC analysis showed significantly higher AUC values for the integrated model at 1 year (0.725 vs. 0.669, p = 0.046), 3 years (0.703 vs. 0.657, p = 0.024), and 5 years (0.684 vs. 0.649, p = 0.031). DCA indicated greater net benefit across clinically relevant thresholds, and calibration plots showed good agreement between predicted and observed survival probabilities. Conclusion: An integrated clinicopathological model incorporating TNM stage, MVI, ALBI grade, and resection margin status improves prognostic performance compared with TNM alone in patients undergoing curative resection for HCC. This model may support more accurate postoperative risk stratification.
- Open Access
- 10 August 2025
- Published by Hue Central Hospital in Tạp chí Y học lâm sàng Bệnh viện Trung Ương Huế
- Vol. 17 (6) , 83-88
Hiệu quả điều trị pembrolizumab phối hợp với lenvatinib trong ung thư biểu mô tế bào thận giai đoạn di căn: 2 ca lâm sàng
Tóm tắt: Phác đồ phối hợp Pembrolizumab và Lenvatinib hiện nay là một trong các lựa chọn điều trị bước một ưu tiên hàng đầu cho ung thư biểu mô tế bào thận di căn (mRCC) nhờ hiệu quả vượt trội về tỉ lệ đáp ứng và thời gian sống thêm so với các phác đồ đơn trị liệu trước đây. Tuy nhiên, tại Việt Nam, hạn chế về chi phí khiến ít bệnh nhân được tiếp cận với phác đồ này. Trong báo cáo này, chúng tôi trình bày hai trường hợp bệnh nhân mRCC được điều trị bằng phác đồ phối hợp Pembrolizumab và Lenvatinib từ tháng 2 năm 2025 đến tháng 8 năm 2025 tại Bệnh viện K. Kết quả điều trị theo RECIST 1.1 bước đầu đạt đáp ứng một phần và hồ sơ độc tính theo CTCAE 5.0 có thể kiểm soát được.
- 10 August 2025
- Published by Hue Central Hospital in Tạp chí Y học lâm sàng Bệnh viện Trung Ương Huế
- Vol. 17 (6) , 83-88
Open AccessHiệu quả điều trị pembrolizumab phối hợp với lenvatinib trong ung thư biểu mô tế bào thận giai đoạn di căn: 2 ca lâm sàng
Tóm tắt: Phác đồ phối hợp Pembrolizumab và Lenvatinib hiện nay là một trong các lựa chọn điều trị bước một ưu tiên hàng đầu cho ung thư biểu mô tế bào thận di căn (mRCC) nhờ hiệu quả vượt trội về tỉ lệ đáp ứng và thời gian sống thêm so với các phác đồ đơn trị liệu trước đây. Tuy nhiên, tại Việt Nam, hạn chế về chi phí khiến ít bệnh nhân được tiếp cận với phác đồ này. Trong báo cáo này, chúng tôi trình bày hai trường hợp bệnh nhân mRCC được điều trị bằng phác đồ phối hợp Pembrolizumab và Lenvatinib từ tháng 2 năm 2025 đến tháng 8 năm 2025 tại Bệnh viện K. Kết quả điều trị theo RECIST 1.1 bước đầu đạt đáp ứng một phần và hồ sơ độc tính theo CTCAE 5.0 có thể kiểm soát được.